

CJC 1295 | Ipamorelin mouth spray 4x homeopathic

Background

CJC 1295 plus Ipamorelin supplement spray is a two-peptide combination intended to mimic Growth Hormone (GH) releasing hormone that activates one side of the pituitary gland to release GH. As an anti-aging supplement, this hormone therapy alternative benefits patients by stimulating muscle growth, fat loss, improving sleep quality, and increasing energy levels through GH secretion. The CJC 1295 Ipamorelin tandem works synergistically with the former acting as a growth hormone-releasing hormone (GHRH) analog and the latter is thought to be a more selective growth hormone secretagogue. Physicians are urged to check current FDA guidelines on the status of these peptides before recommending for patient treatments.

This vibrant peptide pair may boost health and performance, with additional anti-aging abilities in restoration of youthful skin tone. Interestingly, this combination homeopathic mouth spray therapy may offer one of the most potent synergistic effects available in peptide therapy. According to Cochrane (2024), the combined effect is realized as Ipamorelin goes to work to stimulate secretion of growth hormone and then CJC-1295 steps in to prolong the GH activities in the body.³ Similar to other GH therapies, this formulary is designed to promote improvements in metabolism, muscle mass, sleep quality, immunity, and bodily recovery, coupled with decreased fat accumulation.³ The patient outcome is anticipated to be an increase in perceptions of well-being and overall vitality.³ Turner & Char (2024) suggest that CJC 1295 aids to increase the half-life of Ipamorelin, implying that the beneficial activities are extended.⁴ This combination may also promote enhanced cognitive function and libido coupled with protective factors as a potent anti-inflammatory.⁴

Research

CJC 1295 has been clinically investigated. Teichman et al. (2005) set out to explore the pharmacokinetic profile and pharmacodynamic effects of the long-acting GHRH analog employing a two randomized, placebo-controlled, double-blind, ascending dose trials study design examining healthy subjects, ages 21-61.¹ Findings suggest administration of CJC 1295 results in sustained, dose-dependent increases in growth hormone (GH) and insulin like growth factor 1 (IGF-I) levels.¹ Ipamorelin, as an effective GH and IGF-1 activator, may significantly improve body composition while concurrently reducing hypogonadal symptoms like fat gain and muscular atrophy.² Interest in the peptide stems from its mimicking ability of ghrelin (the hunger hormone) and related interactions with the GI tract that can positively affect adiposity and body composition.²

Growth hormone-releasing hormone (GHRH) employed for therapeutic purposes has been criticized for its short half-life and necessity for frequent dosing, however, CJC 1295 + Ipamorelin appears to address some of these concerns by extending GH secretory effects.^{1,4} The synthetic composition of CJC-1295 standalone has shown it to be an active hGRF₁₋₂₉ analog, demonstrating both stability and expanded plasma half-life.⁵ Although there are limited human studies on CJC 1295, researchers are beginning to uncover in animal studies that the synthetic human GHRH analog has prolonged GH activities and half-life based on an ability to bind to endogenous albumin

(globular proteins found in blood plasma) covalently and selectively.^{5,6} The synthetic pentapeptide Ipamorelin, acting as a selective agonist of the ghrelin | GHS receptor route, binds the same GHSR-1a receptor as many popular GH release peptides like GHRP-2 and GHRP-6.^{7, 8, 9} Specifically, according to Wren et al. (2001), interface with GHSR-1a stimulates GH secretion from the pituitary, leading to anabolic activities such as appetite regulation, fat metabolism, and enhanced metabolism.¹⁰

Conclusion

As an anti-aging, two-peptide combination mouth spray, CJC 1295 plus Ipamorelin is designed to mimic Growth Hormone (GH) releasing hormone to secrete GH. Suggested outcomes may include improved body composition, energy levels, and an increase in overall vitality. This vibrant peptide pair is designed as an overall health and performance adjunct, with additional anti-aging abilities such as restoration of youthful skin tone. Interestingly, this combination homeopathic mouth spray therapy may offer one of the most potent synergistic anti-aging tandems available in peptide therapy. Physicians should check the current FDA status of these peptides before recommending them for patient use.

References

- ¹ Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. *J Clin Endocrinol Metab.* 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
- ² Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. *Transl Androl Urol.* 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
- ³ The Synergistic Effects of Ipamorelin and CJC 1295: What You Need to Know. (2024, February 3). <https://www.cochrane-handbook.org/the-synergistic-effects-of-ipamorelin-and-cjc-1295-what-you-need-to-know/>.
- ⁴ Ipamorelin: Health Benefits, Dosage, and Side Effects. (2024, January 16). <https://healthnews.com/family-health/drugs/ipamorelin-uses-and-side-effects/>.
- ⁵ Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. *Endocrinology.* 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.

- ⁶ Iordanova VK, Wen SY, Moreau IA, Smith SY, Frohman LA, and Castaigne JP. Every other day subcutaneous administration of CJC-1295, a drug affinity complex (DAC)-growth hormone releasing factor (GRF) analogue, increases body weight and bone mineral content in dogs (Abstract). 87th Annual Meeting of The Endocrine Society, 2005, p. P1–78.
- ⁷ Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. *Eur J Endocrinol*. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
- ⁸ Kojima M, Kangawa K. Ghrelin: structure and function. *Physiol Rev*. 2005 Apr;85(2):495-522. doi: 10.1152/physrev.00012.2004. PMID: 15788704.
- ⁹ Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. *Pharmacol Rev*. 2005 Dec;57(4):541-6. doi: 10.1124/pr.57.4.1. PMID: 16382107.
- ¹⁰ Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. *J Clin Endocrinol Metab*. 2001 Dec;86(12):5992. doi: 10.1210/jcem.86.12.8111. PMID: 11739476.

All: (a) content or statements appearing in this information paper have not been evaluated by the Food and Drug Administration, (b) product or related claims and provisions are not intended to diagnose, treat, cure, or prevent any disease, (c) content or statements appearing in this document are not intended to substitute for professional medical advice. For educational purposes only.